This is very important, but where is the time to look into price information. There needs to be a better process. In our EMR systems, we are glued on seeing a patient and going to the next patient. The time taken to go to an another portal is impractical.
This is no surprise. The literature on physician feedback consistent shows simple clinical and cost feedback and guidelines are not effective to change behavior.
A more successful process is to stratify the physicians and feedback to outliers their results against their peers AND give them a rationale and evidence to change.
We have successfully changed behavior in hundreds of physicians and Medicaid and the commercial sector when feeding back generic fill rates, dispenses written, cost per drug in a class and given the physicians their numbers compared to appears best in class. The addition of an evidence based newsletter, defining why changes and evidence are necessary enhances the feedback process. We find it for every 1 percent increase generic fill rate there is a 1-1.5 % reduction in overall pharmacy spend. The results are more dramatic when feeds back includes bio similar vs biologic drugs. Depending on the population age and disease categories of 50% increase in bios similars can return huge rewards without any decrement in clinical outcomes.
This is very important, but where is the time to look into price information. There needs to be a better process. In our EMR systems, we are glued on seeing a patient and going to the next patient. The time taken to go to an another portal is impractical.
Better technology is needed!
This is no surprise. The literature on physician feedback consistent shows simple clinical and cost feedback and guidelines are not effective to change behavior.
A more successful process is to stratify the physicians and feedback to outliers their results against their peers AND give them a rationale and evidence to change.
We have successfully changed behavior in hundreds of physicians and Medicaid and the commercial sector when feeding back generic fill rates, dispenses written, cost per drug in a class and given the physicians their numbers compared to appears best in class. The addition of an evidence based newsletter, defining why changes and evidence are necessary enhances the feedback process. We find it for every 1 percent increase generic fill rate there is a 1-1.5 % reduction in overall pharmacy spend. The results are more dramatic when feeds back includes bio similar vs biologic drugs. Depending on the population age and disease categories of 50% increase in bios similars can return huge rewards without any decrement in clinical outcomes.